XML 20 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (21,483,561) $ (16,851,533)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 741,524 721,665
Change in fair value of earn-out milestone liability 1,300,291 (3,189,955)
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments 400,000
Fair value of warrants issued in exchange for services 44,798
Stock-based compensation 1,851,391 2,286,388
Shares issued upon vesting of stock awards 5,350
Change in deferred income tax asset (26,499) (1,819,324)
Impairment of in-process research and development 2,370,257
Amortization of deferred finance charges and debt discount associated with note payable 447,483 386,640
Net changes in:    
Accrued interest receivable on investment securities 21,369 46,940
Advances and deposits on clinical programs and other current assets (308,025) (901,377)
Other assets 274,513 (74,341)
Accounts payable - trade (618,102) (157,689)
Deferred revenue (500,000) (500,000)
Other accrued liabilities 265,885 (611,746)
Net cash used in operating activities (15,618,676) (20,258,982)
Cash flows from investing activities:    
Purchases of investment in debt securities (9,956,892) (23,829,982)
Proceeds from sale and maturity of investment in debt securities 17,900,000 30,115,000
Purchases of property and equipment (19,092) (349,158)
Net cash provided by investing activities 7,924,016 5,935,860
Cash flows from financing activities:    
Proceeds from issuance of common stock equity, net of issuance costs 22,811,669 7,844,852
Proceeds from issuance of common stock upon exercise of stock options 371,895
Payments on notes payable including end-of-term fees (5,200,000)
Proceeds from Paycheck Protection Program ("PPP") loans 1,324,750
Repayments on PPP loans (1,324,750)
Net cash provided by financing activities 17,983,564 7,844,852
Increase (decrease) in cash and cash equivalents 10,288,904 (6,478,270)
Cash and cash equivalents at beginning of year 6,875,273 13,353,543
Cash and cash equivalents at end of year 17,164,177 6,875,273
Cash (paid for) received from:    
Interest (844,278) (1,006,760)
Cash paid for amounts included in measurement of lease liabilities:    
Operating cash flows from lease payments 525,809 485,848
Non-cash financing and investing activities    
Common stock issued to settle accrued bonuses 498,632
Fair value of warrants issued in connection with the debt facility, net of cancelled warrants 81,102
Realized and unrealized (gains) and losses, net, on investment in debt securities $ (42,778) $ 12,906